GLP-1 (Glucagon-like peptide-1) receptor agonists are medications used primarily for type 2 diabetes management, and more recently, for obesity. Some studies have indicated that GLP-1 may have potential anti-cancer effects due to their influence on insulin sensitivity, inflammation, and weight. The GLP-1’s benefit and risk related to post-cancer complications are largely unknown.
A grant proposal is being developed to investigate the longitudinal effects of GLP-1 on post-cancer complications in cancer survivors (a future observational study, leveraging one or more large data sets). This research opportunity would allow for a student to conduct a literature review in this area and describe the evidence knowledge gap, as well as a preliminary survey of available data structures.